全文获取类型
收费全文 | 56594篇 |
免费 | 3807篇 |
国内免费 | 170篇 |
专业分类
耳鼻咽喉 | 639篇 |
儿科学 | 1369篇 |
妇产科学 | 1077篇 |
基础医学 | 7224篇 |
口腔科学 | 1487篇 |
临床医学 | 5722篇 |
内科学 | 11431篇 |
皮肤病学 | 730篇 |
神经病学 | 4867篇 |
特种医学 | 2216篇 |
外国民族医学 | 26篇 |
外科学 | 8945篇 |
综合类 | 673篇 |
一般理论 | 32篇 |
预防医学 | 5113篇 |
眼科学 | 1397篇 |
药学 | 3985篇 |
中国医学 | 95篇 |
肿瘤学 | 3543篇 |
出版年
2022年 | 434篇 |
2021年 | 965篇 |
2020年 | 602篇 |
2019年 | 866篇 |
2018年 | 1059篇 |
2017年 | 783篇 |
2016年 | 911篇 |
2015年 | 1077篇 |
2014年 | 1506篇 |
2013年 | 2266篇 |
2012年 | 3249篇 |
2011年 | 3376篇 |
2010年 | 1898篇 |
2009年 | 1809篇 |
2008年 | 3102篇 |
2007年 | 3141篇 |
2006年 | 3176篇 |
2005年 | 3323篇 |
2004年 | 3162篇 |
2003年 | 2946篇 |
2002年 | 2789篇 |
2001年 | 841篇 |
2000年 | 814篇 |
1999年 | 855篇 |
1998年 | 711篇 |
1997年 | 564篇 |
1996年 | 472篇 |
1995年 | 494篇 |
1994年 | 467篇 |
1993年 | 520篇 |
1992年 | 804篇 |
1991年 | 735篇 |
1990年 | 603篇 |
1989年 | 452篇 |
1988年 | 431篇 |
1987年 | 434篇 |
1986年 | 379篇 |
1985年 | 453篇 |
1984年 | 469篇 |
1983年 | 409篇 |
1982年 | 492篇 |
1981年 | 455篇 |
1980年 | 411篇 |
1979年 | 321篇 |
1978年 | 329篇 |
1977年 | 328篇 |
1976年 | 326篇 |
1975年 | 293篇 |
1974年 | 308篇 |
1973年 | 303篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
The human visual system is amenable to a number of adaptive processes; one such process, or collection of processes, is the adaptation to blur. Blur adaptation can be observed as an improvement in vision under degraded conditions, and these changes occur relatively rapidly following exposure to blur. The potential important future directions of this research area and the clinical implications of blur adaptation are discussed. 相似文献
4.
AbstractGaining a better grasp on factors related to changes in alcohol use is of particular interest for clinicians. Past research has highlighted a negative link between future time perspective (i.e. a disposition guiding how individuals consider and act regarding their future) and alcohol misuse. However, much remains at stake in the understanding of this association. The objective of this research was to explore bidirectional relationships between future time perspective and severity of alcohol-related problems, in a clinical setting. The sample includes 79 patients followed up in an outpatient alcohol treatment centre. Two measurement times were planned: at entry into care and 6 months later. Multiple linear regression analyses were carried out, controlling for sociodemographic variables. We found that baseline future time perspective predicted level of alcohol-related problems after 6 months in treatment, even when effects of baseline alcohol-related problems and sociodemographic variables were controlled. This study shows that the way patients see and position themselves regarding their future can affect level of alcohol-related problems. It may be useful for clinicians to identify patients with low future time perspective to offer tailored interventions and consider this dimension as a resource for change. 相似文献
5.
6.
7.
8.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
9.